Artelo Biosciences, Inc. Enters into Securities Purchase Agreements for Bridge Notes

Artelo Biosciences, Inc. has executed two Securities Purchase Agreements on March 12, 2026, with Vanquish Funding Group Inc. and Boot Capital LLC. These agreements involve the issuance of two bridge notes totaling $350,300.00 in aggregate principal amount, with an original issue discount of $40,300.00, for an aggregate purchase price of $310,000.00. The notes mature on January 15, 2027, and bear a 12% interest rate. The company can prepay the notes without penalty. The proceeds are intended for general working capital. In case of an Event of Default, the outstanding balance, including interest and fees, becomes immediately payable, potentially increased by a 150% Default Percentage. The buyers also have the option to convert the outstanding note balances into the company's common stock under certain conditions, with a conversion price floor and a beneficial ownership limitation of 4.99%. The sales are exempt from registration under the Securities Act, relying on Section 4(a)(2) and Regulation D. The company has also agreed to cover $10,000 of Vanquish's due diligence and legal fees.